Gert J. Ossenkoppele

33.2k total citations · 4 hit papers
279 papers, 12.3k citations indexed

About

Gert J. Ossenkoppele is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Gert J. Ossenkoppele has authored 279 papers receiving a total of 12.3k indexed citations (citations by other indexed papers that have themselves been cited), including 204 papers in Hematology, 87 papers in Molecular Biology and 81 papers in Genetics. Recurrent topics in Gert J. Ossenkoppele's work include Acute Myeloid Leukemia Research (162 papers), Hematopoietic Stem Cell Transplantation (53 papers) and Chronic Myeloid Leukemia Treatments (51 papers). Gert J. Ossenkoppele is often cited by papers focused on Acute Myeloid Leukemia Research (162 papers), Hematopoietic Stem Cell Transplantation (53 papers) and Chronic Myeloid Leukemia Treatments (51 papers). Gert J. Ossenkoppele collaborates with scholars based in Netherlands, United States and Germany. Gert J. Ossenkoppele's co-authors include Bob Löwenberg, Gerrit Jan Schuurhuis, Arjan A. van de Loosdrecht, Hartmut Döhner, Alan K. Burnett, Dietger Niederwieser, Jorge Sierra, Theresia M. Westers, Elihu H. Estey and Miguel Á. Sanz and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Gert J. Ossenkoppele

274 papers receiving 12.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

2009 2.4k citations Hartmut Döhner, Elihu H. Estey et al. Blood profile →
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

2009 596 citations Bob Löwenberg, Gert J. Ossenkoppele et al. profile →
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

2007 540 citations Francis J. Giles, Gert J. Ossenkoppele et al. Blood profile →
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

2022 159 citations Tim Grob, François G. Kavelaars et al. Blood profile →

Peers

Countries citing papers authored by Gert J. Ossenkoppele

Since Specialization

Citations

This map shows the geographic impact of Gert J. Ossenkoppele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gert J. Ossenkoppele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gert J. Ossenkoppele more than expected).

Fields of papers citing papers by Gert J. Ossenkoppele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gert J. Ossenkoppele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gert J. Ossenkoppele. The network helps show where Gert J. Ossenkoppele may publish in the future.

Co-authorship network of co-authors of Gert J. Ossenkoppele

This figure shows the co-authorship network connecting the top 25 collaborators of Gert J. Ossenkoppele. A scholar is included among the top collaborators of Gert J. Ossenkoppele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gert J. Ossenkoppele. Gert J. Ossenkoppele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T‐cell therapy 2025 ·HemaSphere ·(unknown), (unknown), Renée Poels, (unknown), (unknown), (unknown), Jennemiek van Arkel, (unknown), Niels W.C.J. van de Donk, Maria Themeli, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Rebecca M. Richards, Tuna Mutis	0
2	The role of the primitive marker CD133 in CD34‐negative acute myeloid leukemia for the detection of leukemia stem cells 2024 ·Cytometry Part B Clinical Cytometry ·(unknown), (unknown), Lok Lam Ngai, (unknown), (unknown), Willemijn J. Scholten, Angèle Kelder, Diana Hanekamp, (unknown), Noortje van Gils, Patrycja Gradowska, Bob Löwenberg, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Theresia M. Westers, Linda Smit, Costa Bachas, Jacqueline Cloos	3
3	Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia 2024 ·Leukemia ·Jesse M. Tettero, (unknown), (unknown), (unknown), Angèle Kelder, Willemijn J. Scholten, Alexander N. Snel, Lok Lam Ngai, Costa Bachas, Arjan A. van de Loosdrecht, Gert J. Ossenkoppele, David C. de Leeuw, Jacqueline Cloos, Jeroen J. W. M. Janssen	8
4	Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML 2024 ·Blood Advances ·(unknown), Tim Grob, Melissa Rijken, François G. Kavelaars, (unknown), Gert J. Ossenkoppele, Markus G. Manz, (unknown), (unknown), Bob Löwenberg, Peter J.M. Valk	2
5	Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML 2021 ·Cancers ·Anna Wojtuszkiewicz, Inge van der Werf, Stephan Hütter, Wencke Walter, Constance Baer, Wolfgang Kern, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, Claudia Haferlach, Jacqueline Cloos, Torsten Haferlach	4
6	SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia 2021 ·Leukemia ·Inge van der Werf, Anna Wojtuszkiewicz, Huilan Yao, Rocco Sciarrillo, Manja Meggendorfer, Stephan Hütter, Wencke Walter, Jeroen J. W. M. Janssen, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach, Gerrit Jansen, Gertjan J.L. Kaspers, Richard W.J. Groen, Gert J. Ossenkoppele, Jacqueline Cloos	8
7	Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification 2021 ·Blood Advances ·Inge van der Werf, Anna Wojtuszkiewicz, Manja Meggendorfer, Stephan Hütter, Constance Baer, Martijn W. Heymans, Peter J.M. Valk, Wolfgang Kern, Claudia Haferlach, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, Jacqueline Cloos, Torsten Haferlach	23
8	Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting 2020 ·Trials ·(unknown), Kathryn Harrison, Paula Williamson, Brian J.P. Huntly, Gert J. Ossenkoppele, Jan Geißler, (unknown), Jesús María Hernández‐Rivas, Hélène Chevrou‐Séverac, (unknown), Renate Schulze‐Rath, Lars Bullinger	1
9	Minimal residual disease and stem cell transplantation outcomes 2019 ·Hematology ·Jacqueline Cloos, Gert J. Ossenkoppele, Richard Dillon	11
10	Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (>= 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15) 2017 ·Blood ·(unknown), Dana Chiţu, Violaine Havelange, Mojca Jongen‐Lavrencic, (unknown), Bart J. Biemond, (unknown), (unknown), Carlos Graux, (unknown), Okke de Weerdt, Dimitri Breems, Saskia K. Klein, Jürgen Kuball, Gert J. Ossenkoppele, Bob Löwenberg, Edo Vellenga	5
11	Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy 2016 ·Clinical Cancer Research ·Noortje Thielen, Johan Richter, (unknown), Gisela Barbany, Thoas Fioretos, Francis J. Giles, Bjørn Tore Gjertsen, Andreas Hochhaus, Gerrit Jan Schuurhuis, Sieghart Sopper, Leif Stenke, Sarah Thunberg, Dominik Wolf‎, Gert J. Ossenkoppele, Kimmo Porkka, Jeroen J. W. M. Janssen, Satu Mustjoki	14
12	Attenuation of microRNA-126 Expression That Drives CD34+38− Stem/Progenitor Cells in Acute Myeloid Leukemia Leads to Tumor Eradication 2014 ·Cancer Research ·David C. de Leeuw, Fedor Denkers, (unknown), (unknown), Walter Pouwels, Gerrit Jan Schuurhuis, Gert J. Ossenkoppele, Linda Smit	76
13	How I treat the older patient with acute myeloid leukemia 2014 ·Blood ·Gert J. Ossenkoppele, Bob Löwenberg	146
14	MicroRNA Profiling Can Classify Acute Leukemias of Ambiguous Lineage as Either Acute Myeloid Leukemia or Acute Lymphoid Leukemia 2013 ·Clinical Cancer Research ·David C. de Leeuw, Willemijn van den Ancker, Fedor Denkers, Renée X. de Menezes, Theresia M. Westers, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Linda Smit	30
15	AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY ACUTE MYELOID LEUKEMIA 2013 ·Mediterranean Journal of Hematology and Infectious Diseases ·Gert J. Ossenkoppele, Jeroen J. W. M. Janssen, Peter C. Huijgens	3
16	Absence of Class II–Associated Invariant Chain Peptide on Leukemic Blasts of Patients Promotes Activation of Autologous Leukemia-Reactive CD4+ T Cells 2011 ·Cancer Research ·Marvin M. van Luijn, Willemijn van den Ancker, Martine E.D. Chamuleau, Adri Zevenbergen, Theresia M. Westers, Gert J. Ossenkoppele, S. Marieke van Ham, Arjan A. van de Loosdrecht	23
17	Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry 2011 ·Journal of Clinical Oncology ·Roel J.W. van Kampen, Carmen Canals, Harry C. Schouten, Arnon Nagler, Kirsty Thomson, (unknown), Agnès Buzyn, Marc Boogaerts, J.J. Luan, Sébastien Maury, Nöel Milpied, (unknown), Gert J. Ossenkoppele, Anna Sureda	141
18	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet breakdown → 2009 ·Blood ·Hartmut Döhner, Elihu H. Estey, Sergio Amadori, Frederick R. Appelbaum, Thomas Büchner, Alan K. Burnett, Hervé Dombret, Pierre Fenaux, David Grimwade, Richard A. Larson, Francesco Lo‐Coco, Tomoki Naoe, Dietger Niederwieser, Gert J. Ossenkoppele, Miguel Á. Sanz, Jorge Sierra, Martin S. Tallman, Bob Löwenberg, Clara D. Bloomfield	2350
19	Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison 2008 ·Blood ·Jan J. Cornelissen, Bronno van der Holt, Gregor Verhoef, Mars B. van ’t Veer, Marinus H. J. van Oers, Harry C. Schouten, Gert J. Ossenkoppele, Pieter Sonneveld, Johan Maertens, Marinus van Marwijk Kooy, M Schaafsma, Pierre W. Wijermans, Douwe H. Biesma, Shulamit Wittebol, P.J. Voogt, Joke W. Baars, Pierre Zachée, Leo F. Verdonck, Bob Löwenberg, A. W. Dekker	121
20	Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells 2006 ·Blood ·Abdulbaqi Al–Toma, Otto Visser, (unknown), B. Mary E. von Blomberg, Wieke H.M. Verbeek, Petra E.T. Scholten, Gert J. Ossenkoppele, Peter C. Huijgens, Chris J. Mulder	137

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact